Chi‐Chung Chan - Concepedia

Author

Chi‐Chung Chan

Merck Canada Inc. (Canada)

Also Known As

C C Chan, C ‐C Chan, C. -C. Chan, C. C. CHAN, C. C. Chan, C.-C Chan, C.-C. Chan, C.C. Chan, C.‐C. CHAN, Chi-Chung Chan

Publications

7.5K

Citations

H-Index

Concepts

All Affiliations

Merck Canada Inc. (Canada)Merck & Co., Inc., Rahway, NJ, USA (United States)TransCanada (Canada)Stanford Medicine Stanford University

About

Chi‐Chung Chan is an author at Merck Canada Inc. (Canada) specializing in medicine, pharmacology, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	28	3.3K
2	Natural Sciences	13	13	1.5K
3	Allergy	4	4	380
4	Social Sciences	2	2	291
5	Health Sciences	1	1	12

Chi‐Chung Chan

Publications

5.3K

Citations

H-Index

Page 1

	Year	Citations
Dipeptidyl Peptidase IV Inhibition for the Treatment of Type 2 Diabetes George R. Lankas, Barbara Leiting, Ranabir Sinha Roy, Diabetes Diabetes ManagementPharmacological StudyBiochemistryDiabetesPharmacology	2005	490
Etoricoxib (MK-0663): Preclinical Profile and Comparison with Other Agents That Selectively Inhibit Cyclooxygenase-2 Denis Riendeau, M. David Percival, Christine Brideau, Journal of Pharmacology and Experimental Therapeutics	2001	456
The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor Petpiboon Prasit, Z Wang, Christine Brideau, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyMedicinal ChemistryActive Cyclooxygenase-2 InhibitorPharmaceutical ScienceBiochemistry	1999	426
Rofecoxib [Vioxx, MK-0966; 4-(4′-Methylsulfonylphenyl)-3-phenyl-2-(5 H)-furanone]: A Potent and Orally Active Cyclooxygenase-2 Inhibitor. Pharmacological and Biochemical Profiles Chi‐Chung Chan, S. Boyce, Christine Brideau, Journal of Pharmacology and Experimental Therapeutics	1999	397
Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX‐2 inhibitor Denis Riendeau, M. David Percival, S. Boyce, British Journal of Pharmacology Pge2 ProductionChemoprevention StrategyImmunologyPharmacotherapyPharmaceutical Chemistry	1997	326
Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. Chi‐Chung Chan, S. Boyce, Christine Brideau, Journal of Pharmacology and Experimental Therapeutics	1995	313
A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors Christine Brideau, Stacia Kargman, S. Liu, Inflammation Research Therapeutic Drug MonitoringMedicinal ChemistryPharmacological StudyBiochemistryNatural Sciences	1996	281
Quinolines as potent 5-lipoxygenase inhibitors: Synthesis and biological profile of L-746,530 Daniel Dubé, Marc Blouin, Christine Brideau, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryAldehyde DehydrogenaseBiochemistryPotent 5-Lipoxygenase InhibitorsNatural Sciences	1998	271
Deletion of phosphodiesterase 4D in mice shortens α2-adrenoceptor–mediated anesthesia, a behavioral correlate of emesis Annette Robichaud, Panagiota B. Stamatiou, S.-L. Catherine Jin, Journal of Clinical Investigation	2002	266
Deletion of phosphodiesterase 4D in mice shortens α2-adrenoceptor–mediated anesthesia, a behavioral correlate of emesis Annette Robichaud, Panagiota B. Stamatiou, S.-L. Catherine Jin, Journal of Clinical Investigation Type 4Anesthetic MechanismRolipram-sensitive Pde ActivityPharmacotherapyExperimental Pharmacology	2002	258

Page 1